Turnstone Biologics Revenue and Competitors

Claim your profile

Ottawa, ON CAN

Location

$132.7M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Turnstone Biologics's estimated annual revenue is currently $29.1M per year.(i)
  • Turnstone Biologics received $41.4M in venture funding in November 2016.
  • Turnstone Biologics's estimated revenue per employee is $193,750
  • Turnstone Biologics's total funding is $132.7M.

Employee Data

  • Turnstone Biologics has 150 Employees.(i)
  • Turnstone Biologics grew their employee count by 23% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.7M480%$39.4MN/A
#2
$5.5M71-1%$23.8MN/A
#3
$79.8M51519%N/AN/A
#4
$3.7M24-11%N/AN/A
#5
$6.4M41-68%N/AN/A
#6
$17.4M11217%N/AN/A
#7
$14.9M9648%$86MN/A
#8
$27.4M177-31%N/AN/A
#9
$2M138%N/AN/A
#10
$3.3M2162%N/AN/A

Turnstone Biologics is a privately-held immuno-oncology company dedicated to delivering breakthrough viral immunotherapies to improve survival for patients with cancer. With an experienced leadership team passionate about helping people with cancer, comprehensive capabilities in immuno-oncology discovery, basic research, translation, clinical development, manufacturing and commercialization, Turnstone Biologics is the sole company developing viral immunotherapies to drive benefit through simultaneous generation of a targeted immune response and modulation of the tumor environment. The company's engineered oncolytic Maraba virus, known as MG1, is the first therapeutic 2-in-1 approach to combine an oncolytic virus and an antigen-specific cancer vaccine. With its unprecedented dual-mechanism approach, MG1 kills cancer cells both locally and at metastatic sites throughout the body, and generates a durable immune response resulting in long-term memory to prevent recurrence. The company has developed a robust pipeline of new medicines for multiple solid tumors. The most advanced program, called Ad-MG1-MAGEA3, is being evaluated in patients with non-small cell lung cancer (NSCLC), breast cancer and esophageal cancer in two clinical trials. A second Maraba-based therapy designed for patients with human papillomavirus (HPV) positive tumors and multiple other viral immunotherapies are in development. Turnstone Biologics has entered into a research, option and license agreement with AbbVie for its next-generation viral immunotherapies. In 2017, the company was selected as a Fierce 15 winner - a designation signifying that it is considered one of the up-and-coming biotech companies expected to make big waves in the industry. Based in Ottawa, Ontario, and New York, Turnstone Biologics has raised approximately $50 million in venture capital financing since inception.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

$132.7M

Total Funding

150

Number of Employees

$29.1M

Revenue (est)

23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Turnstone Biologics News

2022-04-17 - Health Hires: Ichnos Sciences, Turnstone Biologics

and Turnstone Biologics Corp. have named new general counsel recently, highlighting Law360's latest roundup of personnel moves in health care...

2022-04-17 - Turnstone Biologics Announces TIL Therapy Research ...

Turnstone Biologics Corp., a clinical-stage biotechnology company, is developing new medicines to treat and cure solid tumors by pioneering...

2022-04-13 - Turnstone Biologics Announces Executive Leadership ...

Turnstone Biologics Announces Executive Leadership Appointments. Additions of Venkat Ramanan, Ph.D., as Chief Financial Officer and P. Joseph...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$41.9M1501%N/A
#2
$15M1504%N/A
#3
$15M151-3%N/A
#4
$23.4M152N/AN/A
#5
$37.3M1544%N/A

Turnstone Biologics Funding

DateAmountRoundLead InvestorsReference
2015-10-29$UndisclosedAVersant VenturesArticle
2016-11-03$41.4MBOrbiMedArticle